Literature DB >> 1713605

Presentation of autoantigen by human T cells.

J M LaSalle1, K Ota, D A Hafler.   

Abstract

Activated human T cells express MHC class II and have been shown to present foreign Ag to autologous T cells. We now demonstrate that MHC class II+ T cell clones can present myelin basic protein (MBP) peptide autoantigen in the absence of traditional APC to autologous MBP reactive T cell clones. MBP peptide-pulsed T cell clones specifically stimulated autologous MBP-reactive T cell clones to flux calcium and proliferate. Activation responses were peptide epitope specific and blocked by mAb to MHC class II, indicating a TCR-mediated response. In addition, mAb to the adhesion molecules LFA-3, CD2, LFA-1, CD29, and to the tyrosine phosphatase CD45 also inhibited proliferation, indicating the involvement of T to T cell interactions. In contrast to peptide Ag, T cell clones did not respond to autologous T cells pulsed with HPLC-purified MBP, suggesting that T cells are unable to process whole MBP. However, batch-purified MBP Ag preparations containing lower m.w. breakdown products were presented by T cells, indicating that naturally occurring breakdown products of autoantigens could be presented by activated T cells in vivo. These results raise the possibility that T cell presentation of autoantigen at inflammatory sites may be important in regulation of immune responses to self Ag.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713605

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  B-cell antigens within normal and activated human T cells.

Authors:  G P Sandilands; M Perry; M Wootton; J Hair; I A More
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

Review 2.  T cell-mediated antigen presentation: a potential mechanism of infectious tolerance.

Authors:  M D Mannie
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10.

Authors:  E C Ebert; V Mehta; K M Das
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  Activated rat T cells synthesize and express functional major histocompatibility class II antigens.

Authors:  C P Broeren; M H Wauben; M A Lucassen; M Van Meurs; P J Van Kooten; C J Boog; E Claassen; W Van Eden
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

5.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

6.  Endogenous antigen presentation by autoantigen-transfected Epstein-Barr virus-lymphoblastoid cells. I. Generation of human thyroid peroxidase-reactive T cells and their T cell receptor repertoire.

Authors:  A Martin; R P Magnusson; D L Kendler; E Concepcion; A Ben-Nun; T F Davies
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Ro/SSA inhibits the autologous mixed lymphocyte reaction.

Authors:  J Karsh; J B Harley; R Goldstein; A I Lazarovits
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

8.  Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.

Authors:  Julie M Decker; Kenneth P Zammit; Juliet L Easlick; Mario L Santiago; Denise Bonenberger; Beatrice H Hahn; Olaf Kutsch; Frederic Bibollet-Ruche
Journal:  Virology       Date:  2009-09-12       Impact factor: 3.616

9.  Antigen targeting to antigen-presenting cells enhances presentation to class II-restricted T lymphocytes.

Authors:  A Scardino; M Paroli; G De Petrillo; M L Michel; V Barnaba
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

10.  Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.

Authors:  Cristina Maria Costantino; Hidde L Ploegh; David A Hafler
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.